ID   LN229/mHER2
AC   CVCL_D2SR
RX   DOI=10.3390/ijtm3030022;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 6597; LIFR; Simple; p.Pro1060Ala (c.3178C>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9811; RAD21; Simple; p.Gln132Ter (c.394C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro98Leu (c.293C>T); ClinVar=VCV000528236; Zygosity=Homozygous (from parent cell line).
CC   Transfected with: MGI; MGI:95410; Erbb2.
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: In situ; Brain, right frontal parieto-occipital cortex.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0393 ! LN-229
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 30-01-24; Last updated: 30-01-24; Version: 1
//
RX   DOI=10.3390/ijtm3030022;
RA   Ouchida T., Suzuki H., Tanaka T., Kaneko M.K., Kato Y.;
RT   "Development of highly sensitive anti-mouse HER2 monoclonal antibodies
RT   for flow cytometry.";
RL   Int. J. Transl. Med. 3:310-320(2023).
//